Saturday, November 01, 2025 6:43:19 AM
Slave1, well said, the acquisition of Advent is a truly powerful preparative step toward commercialization.
There are 3 main areas for approval preparedness, the medical science, the mfg capability and the organizational capability.
LP has surprised in how she has prepared the first two. She has layered the foundational science into an unprecedented combination of dendritic cell focused oncological (and other) curative possibilities. She has progressed the medical science into a protected platform which can potentially drive oncological development for years to come and which is exactly what BP's seek, not just single product approaches but deeply scientific platforms which offer longer term depth and breadth development potential. DCVax's science is that to a T!
While it is not a requirement to own the mfg processing it is a significant advantage on several levels if you do when the processing is critically important to the product and constitutes a significant portion of the IP, given the science. While BP's employ CMO's regularly and farm out a portion of their mfg supply chain, they do it with much forethought on short term and longer term product supply and IP protection. In this case no BP would have been comfortable with all mfg expertise being located in a contracted facilty. LP has remedied this at the right time in a particularly investor advantageous way!
Lastly we have not seen the organizational plan for commercialization and continued product platform development but I have to believe, based on the fantastic job LP has done on the first two areas that she also has a well constructed plan for it which we will see in the very near term.
If we had the chance to be on LP's staff we would have known these plans as they were developed years before being shared publicly and we would have saved ourselves a lot of agida. We now understand where LP has methodically positioned NWBO and it is in a very good place.
We also understand the unfair and illegal financial obstacles she has had to overcome along the way, as she is also on the verge of conquering the cabal. Hopefully she is now also showing the path forward for others with life altering medical breakthroughs to success via the court case against the (alleged) criminal seven. Not only has she built a potential oncological powerhouse helping to generate new regulatory steps as she progressed, but she may now help to create new legal restrictions against these financial obstacles which have caused product development delays and therefor unnecessary human suffering.
God Bless all here and GLTA
There are 3 main areas for approval preparedness, the medical science, the mfg capability and the organizational capability.
LP has surprised in how she has prepared the first two. She has layered the foundational science into an unprecedented combination of dendritic cell focused oncological (and other) curative possibilities. She has progressed the medical science into a protected platform which can potentially drive oncological development for years to come and which is exactly what BP's seek, not just single product approaches but deeply scientific platforms which offer longer term depth and breadth development potential. DCVax's science is that to a T!
While it is not a requirement to own the mfg processing it is a significant advantage on several levels if you do when the processing is critically important to the product and constitutes a significant portion of the IP, given the science. While BP's employ CMO's regularly and farm out a portion of their mfg supply chain, they do it with much forethought on short term and longer term product supply and IP protection. In this case no BP would have been comfortable with all mfg expertise being located in a contracted facilty. LP has remedied this at the right time in a particularly investor advantageous way!
Lastly we have not seen the organizational plan for commercialization and continued product platform development but I have to believe, based on the fantastic job LP has done on the first two areas that she also has a well constructed plan for it which we will see in the very near term.
If we had the chance to be on LP's staff we would have known these plans as they were developed years before being shared publicly and we would have saved ourselves a lot of agida. We now understand where LP has methodically positioned NWBO and it is in a very good place.
We also understand the unfair and illegal financial obstacles she has had to overcome along the way, as she is also on the verge of conquering the cabal. Hopefully she is now also showing the path forward for others with life altering medical breakthroughs to success via the court case against the (alleged) criminal seven. Not only has she built a potential oncological powerhouse helping to generate new regulatory steps as she progressed, but she may now help to create new legal restrictions against these financial obstacles which have caused product development delays and therefor unnecessary human suffering.
God Bless all here and GLTA
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
